Plasma Aβ 42 /Aβ 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum

INTRODUCTION: The availability of amyloid beta (Aβ) targeting therapies for Alzheimer's disease (AD) is increasing the demand for scalable biomarkers that are sensitive to early cerebral Aβ accumulation. METHODS: and cognition and cross-sectional associations with SAMS memory and tau positron emission tomography (PET) were examined. RESULTS: was associated with poorer hippocampal-dependent memory and elevated tau accumulation. DISCUSSION: is a scalable assay for detection of cerebral Aβ and prediction of risk for cognitive decline across the AD continuum. HIGHLIGHTS: was sensitive to memory and tau burden in clinically unimpaired older adults.